HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Expanding Naloxone Access Needs Normalizing First-Aid Use, Keeping Purchase Records Private

Executive Summary

Opposition to making naloxone available OTC remains strident because of stigma surrounding drug overdoses, says Bobby Mukkamala, a head and neck surgeon and an AMA Board of Trustees member.

You may also be interested in...



US FDA Expects No Change In Naloxone Access Barrier If Prices High For Potential OTC Products

FDA and non-profit firm Harm Reduction Therapeutics head Michael Hufford agree consumers could pay more out-of-pocket for OTC product than they do in co-pays for insurance plans. But Hufford says consumers’ costs for HRT’s OTC naloxone product won’t be impediment to expanding access.

Australian Pharmacists Support Providing Nonprescription Naloxone But Training Unavailable

Two studies revealed a lack of knowledge by pharmacists in Australia about providing naloxone despite being available without a prescription from pharmacists since 2016. Results could be an indication of potential problems if the opioid antagonist is made available nonprescription in US. 

Naloxone OTC Switch Urged By Congressional Coalition Of 30 Democrats And Republicans

In response to highest number of overdose deaths in US history in 2021, 30 members from both chambers of Congress sign letters sent to seven CEOs of naloxone manufacturers.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel